Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 238,152 Shares

by · The Cerbat Gem

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CEO Eric Lefkofsky sold 238,152 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $68.39, for a total transaction of $16,287,215.28. Following the transaction, the chief executive officer owned 161,848 shares of the company’s stock, valued at approximately $11,068,784.72. This trade represents a 59.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

Shares of NASDAQ TEM traded up $2.21 during trading on Thursday, hitting $70.69. The company had a trading volume of 6,571,301 shares, compared to its average volume of 7,384,247. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The business’s 50-day moving average is $54.37 and its 200 day moving average is $51.71. The company has a market cap of $12.75 billion, a P/E ratio of -49.09 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30.

Tempus AI (NASDAQ:TEM – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same period in the previous year, the firm posted ($0.22) EPS. The company’s quarterly revenue was up 21.6% on a year-over-year basis. Equities research analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

Several hedge funds have recently added to or reduced their stakes in TEM. JPL Wealth Management LLC bought a new stake in Tempus AI during the 3rd quarter worth approximately $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Tempus AI in the fourth quarter worth $27,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Tempus AI during the 3rd quarter worth about $38,000. EMC Capital Management bought a new position in shares of Tempus AI in the 2nd quarter valued at about $29,000. Finally, Danske Bank A S acquired a new position in shares of Tempus AI during the 3rd quarter worth approximately $48,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TEM. HC Wainwright lowered their price target on Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research report on Friday, July 31st. Freedom Capital raised shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Weiss Ratings raised Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Finally, Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $65.69.

Read Our Latest Analysis on TEM

Tempus AI Company Profile

(Get Free Report)

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Featured Stories